All News

High prices can negatively affect patient access and adherence.

A botanically-derived formula was found to heal cold sores in as little as 1 day.

The FDA’s acceptance of the application paves the way for an early review time.

Probiotics are misuderstood in their mechanisms of actions.

The new mobile app gives those with type 2 diabetes accurate insulin doses with an 'on-the-go' convenience.

Seladelpar would be indicated for patients with primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA or as a monotherapy in adults unable to tolerate UDCA.

A Senzer medical device for delivering pharmaceutical-grade cannabinoids has been granted ISO certification for Design and Development.

The needed-free treatment option, ARS-1, is designed to be easy-to-use, convenient and more reliable than other emergency epinephrine treatments for severe allergic reactions.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Non-steroidal anti-inflammatory drugs are now the most common therapeutic drug group for this group in the Golden State, according to a new study.

Researchers at Brigham and Women’s Hospital set out to evaluate the effects of switching insulins in those with type 2 diabetes.

The New Drug Application for upadacitinib is supported by data from the phase 3 SELECT trial program evaluating patients with moderate-to-severe rheumatoid arthritis.

The FDA has approved the Biologics License Application for Novo Nordisk’s long-acting factor VIII replacement treatment for adults and children with hemophilia A.

Turoctocog alfa pegol, also known as N8-GP (Esperoct, Novo Nordisk), is indicated for adults and children with hemophilia A.

Officials with the FDA have granted approval to Merck’s pembrolizumab (Keytruda) for the adjuvant treatment of melanoma with involvement of lymph node(s) following complete resection.

Pembrolizumab (Keytruda, Merck) is the first anti-PD-1 therapy approved in the adjuvant setting across patients with stage 3 melanoma.

Officials with the FDA have approved Xellia Pharmaceuticals’ Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag, according to the company.

Pembrolizumab (Keytruda) plus axitinib (Inlyta) was evaluated in a clinical trial of patients with clear-cell metastatic renal cell carcinoma.

Blocking the interaction between interleukin-33 and regulatory T cells may serve as a new therapeutic target for cancers associated with chronic inflammatory diseases.

Top news of the day across the health care landscape.

MDNA55 prolonged survival in IL4R-positive patients with recurrent glioblastoma in a phase 2b clinical trial.

Prevalence of cognitive impairment has increased among the HIV population while services for diagnosing and treating afflicted individuals remains scarce.

Top news of the day across the health care landscape.

We should all focus on the pharmacist and not the degree.

The sBLA is based on data showing significant improvement in overall survival and progression-free survival in patients with advanced renal cell carcinoma.

Data from an analysis of multiple phase 3 studies highlight improvements in mobility, self-care, and usual activities for patients with moderate-to-severe psoriasis taking secukinumab (Cosentyx).

The study through Penn State College of Medicine adds to existing research on the benefits of medical cannabis in cancer cases.

What is causing this young, healthy woman to lose her hair?

Top news of the day across the health care landscape.